Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure I: Introduction01:27

Heart Failure I: Introduction

1.0K
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
1.0K
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

4.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.1K
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

482
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.1K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.1K
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

476
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
476
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Linking Lipidomics to Vulnerable Coronary Plaques: A PROSPECT II Substudy.

Arteriosclerosis, thrombosis, and vascular biology·2026
Same author

Outcomes in the BETAMI-DANBLOCK trial compared with a Norwegian nationwide myocardial infarction population.

European heart journal·2026
Same author

Exploring Sex-Specific High-Sensitivity Cardiac Troponin Thresholds for Rule-Out of Non-ST-Elevation Myocardial Infarction.

Clinical chemistry·2026
Same author

Contrast dose determined by body weight and tube potential in coronary CT angiography improves attenuation consistency and reduces contrast dose.

European journal of radiology open·2026
Same author

Assessment of Guidewire-Induced Deviation in Fractional Flow Reserve: Impact of Lesion Morphology and Pressure Guidewire Malposition.

International journal for numerical methods in biomedical engineering·2025
Same author

Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.

The New England journal of medicine·2025

Related Experiment Video

Updated: Feb 26, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K

Heart failure etiology and lipoprotein subfractions: Insight from the SMARTEX-HF study.

Trine Karlsen1,2, Elisabeth K Vesterbekkmo2,3,4, Torstein Hole5,6

  • 1Faculty of Nursing and Health Sciences, Nord University, Bodø, Norway.

International Journal of Cardiology. Heart & Vasculature
|February 25, 2026
PubMed
Summary

Non-ischemic cardiomyopathy patients have higher levels of atherogenic lipoproteins, linked to left ventricular function. Further research is needed to confirm the prognostic significance of these lipoprotein subfractions in heart failure.

Keywords:
CardiomyopathyHDLHeart failureIDLLDLVLDL

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Related Experiment Videos

Last Updated: Feb 26, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

2.1K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.2K

Area of Science:

  • Cardiovascular Medicine
  • Lipid Metabolism
  • Heart Failure Research

Background:

  • Investigated the link between heart failure causes and lipoprotein subfractions.
  • Explored associations between lipoprotein subfractions and left ventricular function in heart failure with reduced ejection fraction (HFrEF) patients.

Purpose of the Study:

  • To determine the relationship between heart failure etiology and lipoprotein subfractions.
  • To explore associations between lipoprotein subfractions and left ventricular dimensions and function in HFrEF patients.

Main Methods:

  • Cross-sectional study of 205 HFrEF patients.
  • Utilized 1H-Nuclear Magnetic Resonance spectroscopy to analyze serum levels of triglycerides, cholesterol, and various lipoprotein subfractions (VLDL, IDL, LDL, HDL, Apolipoproteins A-1, A-2, B).

Main Results:

  • Non-ischemic cardiomyopathy (NICM) patients exhibited significantly higher levels of 48 lipoproteins, including LDL, VLDL, and HDL subfractions, compared to ischemic cardiomyopathy (ICM) patients.
  • NICM patients had elevated cholesterol, remnant cholesterol, and atherogenic apolipoprotein B (ApoB)-containing subfractions.
  • Triglyceride content in certain VLDL and LDL subfractions showed a weak association with left ventricular end-diastolic volume, diameter, ejection fraction, and S' wave velocity.

Conclusions:

  • NICM patients possess a greater atherosclerotic lipoprotein burden, partly due to reduced statin use.
  • The triglyceride content of specific VLDL and LDL subfractions weakly correlates with cardiac structure and function.
  • Further investigation is required to establish the prognostic value of these findings for heart failure management and prevention strategies.